Morgan Stanley Sichuan Kelun Pharmaceutical (002422): Additional ASCO and Investor Call Takeaways on OptiTROPLung05 for Sac-TMT
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
Morgan Stanley provides additional insights on Sichuan Kelun Pharmaceutical (002422) following ASCO presentations and a dedicated investor call focused on the OptiTROPLung05 trial involving Sac-TMT in non-small cell lung cancer (NSCLC). The report indicates that the therapy demonstrated clinically meaningful efficacy in the NSCLC setting. During the investor call, management emphasized Sac-TMT's potential competitive differentiation, particularly regarding an improved safety profile. However, the regulatory pathway remains incompletely defined, and additional supporting data will be required to clarify the submission strategy. While the commentary references encouraging objective response rates (ORR) and disease control rates (DCR), specific quantitative figures were not detailed. Kelun's recent share price volatility reflects broader market hesitancy as participants await further clinical validation. Morgan Stanley notes that the competitive landscape for NSCLC therapies remains intense, adding a layer of complexity to the asset's commercial outlook. The bank maintains its existing rating on Kelun Pharmaceutical but did not assign a specific target price. Looking forward, the principal catalysts include subsequent clinical trial readouts and regulatory agency interactions. Downside risks encompass escalating competition from rival drug candidates and the potential for disappointing future clinical results.